Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
- Mochida Will Groom Lialda into Flagship Quickly: President
January 27, 2017
- Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
- Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
- Pfizer Adjusts Shipments for Tazopipe, Voluntarily Recalls Metformin Generics
January 27, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Takara Bio to Initiate PI/II Trial of Gene Therapy for Synovial Sarcoma
January 25, 2017
- Rohto Anticipates Large-Scale Stem Cell Production Using Automated System, Will Submit Clinical Trial Plan for Cirrhosis this Spring
January 25, 2017
- Napabucasin Add-On Shows Efficacy in Colorectal Cancer: Sumitomo Dainippon
January 24, 2017
- Takecab Most Heavily Pitched Drug in HP Market in November: Anterio
January 24, 2017
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO
January 23, 2017
- Stivarga Gets Priority Review for 2nd-Line Liver Cancer Treatment
January 23, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Towa
January 23, 2017
- BMS-Ono Pair, Merck Settle Keytruda Patent Suits
January 23, 2017
- Opdivo Extends OS in Advanced Gastric Cancer: Ono
January 23, 2017
- Takeda Taps NY Biotech to Develop Its Pediatric Epilepsy Med
January 20, 2017
- Daiichi Sankyo’s 2nd ADC Now in Japan PI/II for HER3-Positive Breast Cancer
January 20, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…